Navigation Links
New Shire Holding Company Proposal
Date:4/16/2008

BASINGSTOKE, England and PHILADELPHIA, April 16 /PRNewswire-FirstCall/ -- Shire plc ("Shire" or the "Company") (LSE: SHP) (NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that further to yesterday's announcement regarding Shire's new holding company proposal, it will today post the Circular and associated documents to its shareholders. A Prospectus, in relation to the ordinary shares in the new Shire holding company, to be called Shire Limited, has been published and both the Prospectus and Circular have been posted on the Company's website: http://www.shire.com.

Copies of the Circular and Prospectus have been submitted to the UK Listing Authority and are available for inspection at the Document Viewing Facility, which is situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS, tel. +44-20-7066-1000.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shire to Introduce a New UK Listed Holding Company
2. Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
3. Shire plc: Long Term Incentive Plan
4. Shire plc: IFRS Results for the Year Ending December 31, 2007
5. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
6. Shire plc: Correction Re Website
7. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
8. Shire Engages Palio
9. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
10. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
11. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... YARDLEY , Pennsylvanie, 18 septembre 2014 ... Lyon en 1974, a été ... à compléter les évaluations cliniques traditionnelles par ... Reported Outcomes) et sur les impacts économiques ... http://photos.prnewswire.com/prnh/20140618/119365 A cours ...
(Date:9/18/2014)... Now a team led by an engineer at Michigan ... that will let scientists slash the cost of one ... Syringe pumps are used to dispatch precise amounts of ... a reaction. They can also cost hundreds or even ... of Michigan Tech students published the library of free ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Silicon-valley Electronic ... with Digitaliza TXT , the latest addition to ... its Clinical Research Organization (CRO) Program, Clinovo further expands ... three days of ClinCapture training, we are now able ... CEO Ana Pulido. “We can also rely on Clinovo ...
(Date:9/17/2014)... 2014 A long-term retrospective study of ... (APBI) via interstitial brachytherapy suggests that women younger ... could be suitable to receive the treatment. Current ... these patients in the "unsuitable" category for APBI. ... meeting, Beaumont Health System,s Peter Y. Chen ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Doing science just got cheaper -- and faster 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4
... to complement VAP advanced cholesterol profileORLANDO, Fla. and ... of the VAP Cholesterol Test, has announced the ... at ACC.09, the American College of Cardiology (ACC) ... more than a dozen new tests, including C-Reactive ...
... January, the industry seems to have taken a deep breath and a step ... cuts that were announced were mostly due to the overall economic difficulty facing ... ... to say the worst is past for health care, it does seem as ...
... Phase 3 programCRANBURY, N.J., March 28 Amicus Therapeutics ... from its ongoing Phase 2 extension study of its ... The results will be presented at the American College ... FL. Phase 2 Extension Study Overview: Twenty-six ...
Cached Biology Technology:Atherotech Unveils New Cardiometabolic Test Panels 2Atherotech Unveils New Cardiometabolic Test Panels 3The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health 3Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 2Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 3Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 4Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 5
(Date:9/18/2014)... A team of researchers from McGill University and ... form of polyethylene ,microbeads, Canadian Journal of ... likely originate from cosmetics, household cleansers, or industrial ... abrasives. Owing to their small size and buoyancy, ... Microplastics are a global contaminant in the ...
(Date:9/18/2014)... spoken language is unique to humans. "The genetic changes ... human evolution to make this possible are largely unknown, ... have," says Wolfgang Enard, Professor of Anthropology and Human ... molecular biological basis of language Enard has now taken ... study, undertaken in collaboration with scientists at several universities, ...
(Date:9/18/2014)... 18, 2014Many Americans across racial and ethnic groups ... impact on their day-to-day life, more so than ... and speech (57% of African-Americans, 49% of non-Hispanic ... When asked which disease or ailment is the ... first among African-Americans followed by AIDS/HIV. Hispanics ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... Di Benedetto and Micaela Caramellino, two doctoral ... received recognition at a student poster event organized ... nano- and micro-sized drug particles. The New Jersey ... was the sponsor. In recent years, ...
... Technology Business Assessment Group will fund four faculty ... identified these one-year projects from a number of ... earlier this spring. Funding for the program ... Property Management, and is generated by royalties from ...
... released today in the online edition of Physiological Genomics finds ... sugary foods. The study offers the first evidence of the ... gene that controls sugar entry into the cells has ... foods high in sugar. The study was conducted ...
Cached Biology News:NJIT doctoral students receive recognition at poster competition 2OSU technologies funded for development 2OSU technologies funded for development 3Genetic variation linked to sugary food 2Genetic variation linked to sugary food 3
Request Info...
Request Info...
Request Info...
... Versatile state of the Art GLP ... to dual 38,000 L fermentation. ... to production. Aseptic operation capable ... Fed-Batch, and Continuous Modes. Hosts ...
Biology Products: